These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 15897593)

  • 21. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
    Langer SW; Thougaard AV; Sehested M; Jensen PB
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):573-6. PubMed ID: 22143379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Wexler LH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of dexrazoxane.
    Hochster HS
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M
    Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
    Synold TW; Tetef ML; Doroshow JH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):93-9. PubMed ID: 9768830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.
    Attia SM; Al-Anteet AA; Al-Rasheed NM; Alhaider AA; Al-Harbi MM
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):837-45. PubMed ID: 19184016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
    Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
    N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
    Kik K; Szmigiero L
    Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
    Tyson AM; Gay WE
    Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Swain SM
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
    Langer SW; Sehested M; Jensen PB
    Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
    de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
    Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
    Schroeder PE; Jensen PB; Sehested M; Hofland KF; Langer SW; Hasinoff BB
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):167-74. PubMed ID: 12750840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
    Gersl V; Bajgar J; Hrdina R; Mazurová Y; Machácková J; Cerman J; Suba P
    Gen Physiol Biophys; 1999 Dec; 18(4):335-46. PubMed ID: 10766032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.